

CLINICAL VIGNETTE

CHEK2 Mutation and Cancer Risk

Melissa Gee, MD and Kristin Masukawa, MD

A 58-year-old female with a 59-year-old sister with breast cancer and BRCA1 mutation. The patient was seen by genetics and found to have CHEK2 and ATM mutations.

Per genetics report, patient had CHEK2, Exon11.c.1232 G>A (p.Trp411*), which is associated with a predisposition to breast, colon, thyroid and prostate cancers. She also demonstrated ATM, Exon52.c.7816 A>G (p.Ile2606Val) this variant has been observed in an individual with colon cancer; and ATM, Gain(Exons 62-63), copy number = 3, which has been observed in patients with colon and renal cancer.

Our patient's ATM mutations were reported as uncertain significance due to insufficient evidence to determine the role of this variant in disease. Patient had an unremarkable colonoscopy 2 years prior and was advised to repeat colonoscopy in 10 years. The recommendation was made prior to knowledge of patient's CHEK2 mutation.

Discussion

CHEK2 (cell cycle checkpoint kinase 2) is a gene that is a cell cycle checkpoint regulator and tumor suppressor that becomes activated upon DNA damage.¹ A mutation in CHEK 2 can increase a patient's cancer risk for breast, colon, thyroid and prostate cancers.

There is also some evidence that a CHEK2 mutation confers an increased risk of stomach cancer, sarcoma and kidney cancer.² As there are several variants of CHEK2 mutations, the risk is based on the individual's gene mutation and family history.³

Among patients with family history of breast cancer that test negative for BRCA1 and BRCA2, 12% demonstrate a large genomic deletion or duplication of one of these genes, and approximately 5% demonstrate a mutation to CHEK2 or TP53.⁴ The lifetime risk for breast cancer for a woman with CHEK2 mutation and no family history is around 20%.⁵ This underscores the importance of a genetics evaluation for patients with a significant family history of breast cancer to determine if they also carry a mutation that will increase their lifetime risk of breast cancer or require monitoring for additional cancer risks.

Current recommendations for breast, colon, thyroid and prostate cancer screening for patients with CHEK2 mutation are summarized below.

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, recommends patients with CHEK2 mutation should undergo annual mammogram beginning at 40 years old, with consideration of annual breast MRI. There was insufficient evidence for risk-reducing mastectomy, but may be considered based on family history.⁶

Due to the increased risk of colon cancer with the CHEK2 mutation,^{7,8} the NCCN Guidelines recommend those with CHEK2 mutation to be managed similarly to those with adenomatous polyposis coli (APC) I1307K mutation which involves colonoscopy screening every 5 years beginning at age 40 or 10 years prior to age of first-degree relative's age at CRC diagnosis. Recommendations will differ if the patient has polyps or colorectal cancer.⁹

There is no current high-level evidence to support thyroid cancer screening. However, patients with familial adenomatous polyposis (FAP) have a hereditary colon cancer syndrome with an increased chance of developing other cancers including thyroid cancer. Some studies evaluated the use of thyroid ultrasound to screen for early thyroid cancer in these patients.^{10,11} At this time the NCCN does not recommend screening for thyroid cancer in patients with CHEK2 mutation. Similarly, USPSTF advises against screening for thyroid cancer in asymptomatic adults.

There are no specific screening guidelines for prostate cancer screening in CHEK2 mutation carriers at this time. African-American men and those with BRCA 1/2 mutation are recommended to begin shared decision making about PSA screening at age 40 years and consider annual screening.¹² Generally, the NCCN recommends patients with family or personal history of high-risk germline mutations be referred to a cancer genetics professional.

Our patient's individualized plan, includes annual screening mammography in addition to annual breast MRI since her calculated lifetime risk of breast cancer was >20%.¹³ Her initial colonoscopy was negative and will be repeated in 5 years. We will continue to see the patient annually and do additional testing/screening if indicated. With regards to genetic screening recommendations for her family members, there are different

guidelines based on the expert group. This patient's sister is BRCA1 positive. The NCCN recommends genetics referral for all first and second-degree relatives of the BRCA1 mutation carrier for discussion of genetic testing and counseling.⁶

Each patient's family history and specific mutation will impact their risk uniquely, emphasizing the importance of genetics consultation to carefully evaluate the risks to the patient. The expanding body of literature on known, recently identified, and future understandings of mutations makes it important to routinely reevaluate cancer risk in patients with known mutations and consider potential modifications to their cancer screening plan, as well as the consideration of additional genetic screening for family members as new gene sequences are discovered.

REFERENCES

1. U.S. National Library of Medicine. CHEK2 gene. <https://ghr.nlm.nih.gov/gene/CHEK2#conditions>. Published August 17, 2020. Accessed October 26, 2020.
2. **Näslund-Koch C, Nordestgaard BG, Bojesen SE.** Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study. *J Clin Oncol.* 2016 Apr 10;34(11):1208-16. doi: 10.1200/JCO.2015.63.3594. Epub 2016 Feb 16. PMID: 26884562.
3. **Gronwald J, Cybulski C, Piesiak W, Suchy J, Huzarski T, Byrski T, Gorski B, Debnia T, Szwiec M, Wokolorczyk D, Matuszewski M, Sun P, Lubinski J, Narod SA.** Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband. *Br J Cancer.* 2009 May 5;100(9):1508-12. doi: 10.1038/sj.bjc.6605038. PMID: 19401704; PMCID: PMC2694428.
4. **Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC.** Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. *JAMA.* 2006 Mar 22;295(12):1379-88. doi: 10.1001/jama.295.12.1379. PMID: 16551709.
5. **Cybulski C, Wokolorczyk D, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Masojć B, Debnia T, Górski B, Blecharz P, Narod SA, Lubiński J.** Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. *J Clin Oncol.* 2011 Oct 1;29(28):3747-52. doi: 10.1200/JCO.2010.34.0778. Epub 2011 Aug 29. PMID: 21876083.
6. NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Genetic/Familial High-Risk Assessment: Breast, Ovarian and Pancreatic. v.1.2021. Updated September 8, 2020. Accessed October 26, 2020.
7. **Liu C, Wang QS, Wang YJ.** The CHEK2 I157T variant and colorectal cancer susceptibility: a systematic review and meta-analysis. *Asian Pac J Cancer Prev.* 2012;13(5):2051-5. doi: 10.7314/apjcp.2012.13.5.2051. PMID: 22901170.
8. **Xiang HP, Geng XP, Ge WW, Li H.** Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility. *Eur J Cancer.* 2011 Nov;47(17):2546-51. doi: 10.1016/j.ejca.2011.03.025. Epub 2011 Jul 30. PMID: 21807500.
9. NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Genetic/Familial High-Risk Assessment: Colorectal. v.1.2020. Updated July 21, 2020. Accessed October 26, 2020.
10. **Feng X, Milas M, O'Malley M, LaGuardia L, Berber E, Jin J, Metzger R, Mitchell J, Shin J, Burke CA, Kalady M, Church J, Siperstein A.** Characteristics of benign and malignant thyroid disease in familial adenomatous polyposis patients and recommendations for disease surveillance. *Thyroid.* 2015 Mar;25(3):325-32. doi: 10.1089/thy.2014.0107. Epub 2015 Feb 9. PMID: 25585202.
11. **Herraiz M, Barbesino G, Faquin W, Chan-Smutko G, Patel D, Shannon KM, Daniels GH, Chung DC.** Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations. *Clin Gastroenterol Hepatol.* 2007 Mar;5(3):367-73. doi: 10.1016/j.cgh.2006.10.019. Epub 2007 Jan 26. PMID: 17258512.
12. NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Prostate Cancer Early Detection. v.2.2020. Updated August 24, 2020. Accessed October 26, 2020.
13. **Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA; American Cancer Society Breast Cancer Advisory Group.** American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. *CA Cancer J Clin.* 2007 Mar-Apr;57(2):75-89. doi: 10.3322/canjclin.57.2.75. Erratum in: *CA Cancer J Clin.* 2007 May-Jun;57(3):185. PMID: 17392385.